Coiled Therapeutics plc (AIM:COIL)

Market Cap	40.46M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	425.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,385
Open	9.50
Previous Close	9.00
Day's Range	9.00 - 10.00
52-Week Range	6.75 - 30.00
Beta	-0.37
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Coiled Therapeutics

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company’s lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical...

• Industry: Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices
• CEO: Sridhar Vempati
• Employees: 7
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: COIL

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 17, 2026

Data Sources Report a data error